Oncotelic Therapeutics has received a contract from the US Biomedical Advanced Research and Development Authority (BARDA) to develop OT-101 to treat the long-term effects of respiratory distress after Covid-19 infection.

Under the contract, the company will collect long-term clinical data from patients with Covid-19 in Peru and Argentina, where the C001-2020-01 trial was carried out.

The data will show the therapy’s potential effectiveness for the treatment of the long-term effects of respiratory distress caused by Covid-19.

Oncotelic stated that the data would be used for designing the next clinical trial to demonstrate OT-101’s effectiveness against long-term Covid-19 as well as the disease.

Antisense against TGF-β2, OT-101 is also developed to treat solid tumours and patients with colorectal carcinoma, pancreatic carcinoma, malignant melanoma, high-grade glioma (HGG), as well as other TGF-β2 overexpressing malignancies.

It has already completed seven clinical trials, which include two Phase II trials in brain cancer and pancreatic cancer and one Phase II randomised, double-blind, placebo-controlled trial in Covid-19 in South America.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The company noted that OT-101 also holds a paediatric designation to treat a rare form of paediatric brain cancer, which is known as DIPG.

The Administration for Strategic Preparedness and Response; Department of Health and Human Services; and Biomedical Advanced Research and Development Authority provided funding for the project in whole or part with federal funds.

In November last year, Oncotelic reported that OT-101 met the safety and efficacy endpoints of the Phase II C001 clinical trial, which was conducted in severe Covid-19 patients admitted to the hospital.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now